Astellas To Invest ¥5.5 Billion To Construct Chemical Compounds Factory For New Drug Development
This article was originally published in PharmAsia News
Executive Summary
Astellas announced April 7 plans to build a chemical compounds production facility at its Toyama factory. The company plans to invest ¥5.5 billion and start the construction in September. To be completed in 2010, the 9,000 square meter, three-story facility will manufacture multiple compounds to be used in clinical trails for new drug development. Currently, Astellas manufactures atopic drug Protopic (tacrolimus), a chemical compound developed from fermented natural products at the Toyama factory; the company plans to manufacture similar compounds at the new facility. (Click here for more - Japanese language